AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03382925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical interlaminar with normal saline
Description: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
Study NCT02832999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sub cutaneous liraglutide
Description: Liraglutide 1.2mg/day
Study NCT02832999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vildagliptin
Description: Vildagliptin 50mg/day
Study NCT02595749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02595749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01047501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 4 g/day
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
Study NCT01047501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 2 g/day
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
Study NCT00811629 — intervention group
Intervention type: OTHER
Intervention: sRAGE
Description: The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
Study NCT01047501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules/day for 12 weeks
Study NCT00689832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03%
Description: ointment
Study NCT00689832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 0.005%
Description: ointment
Study NCT03415256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive vibration
Description: The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
Study NCT03415256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no passive vibration
Description: The control group will not receive any treatment and continue their usual lifestyle.
Study NCT00005988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00005988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00005988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00005988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00005988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00005988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated bone marrow transplantation
Study NCT00005988 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02072044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT03406468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
Study NCT02049762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
Study NCT02049762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
Study NCT00741611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Mesh Ablation System
Description: Ablation using the HD Mesh Ablation System
Study NCT00741611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-arrhythmic drugs
Description: 5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
Study NCT04424901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose while hospitalized up to 9 days
Study NCT04424901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole Tablets
Description: Daily dose while hospitalized up to 9 days
Study NCT01286324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile High Grade Extract
Description: three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
Study NCT01286324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Study NCT02813460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study NCT01413269 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
Study NCT01413269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
Study NCT00351715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Methadone
Study NCT01014715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phase II - Preoperative Radiation followed by Lumpectomy.
Description: Sequential investigative question. All procedures are standard of care
Study NCT01810809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: articular lavage with saline injection
Description: Patients will receive articular lavage with saline injection
Study NCT01810809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: articular lavage with saline injection
Description: Patients will receive articular lavage with saline injection
Study NCT01810809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 ampoule of Hylan GF-20
Description: Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
Study NCT01810809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ampoules of Hylan GF-20
Description: Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
Study NCT01810809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 ampoules of Hylan GF-20
Description: Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
Study NCT04288024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-shifting training
Description: Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time.
Study NCT03382925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.
Study NCT03382925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.
Study NCT03382925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
Study NCT01780870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss group (Full meal replacement products)
Description: In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
Study NCT01334632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous interscalene block
Description: The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
Study NCT01334632 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCA morphine
Description: Postoperative with iv self-administration of morphine
Study NCT01602419 — intervention group
Intervention type: OTHER
Intervention: Patients using Wilate as standard of care
Description: Patients with von Willebrand Disease using Wilate for a period of 2 years.
Study NCT01773590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rhinovirus Infection
Study NCT02503293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Chrono Super PID then Generic Syringe-Gammanorm
Description: Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection
Study NCT02503293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Generic Syringe then Chrono Super PID-Gammanorm
Description: Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection
Study NCT00487565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using a posterior stabilized implant
Study NCT03472105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: New Nordic Renal Diet
Description: One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
Study NCT03472105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Nordic Renal Diet
Description: One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
Study NCT01926912 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
Study NCT03324178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
Study NCT03324178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
Study NCT03961425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NO CO2
Description: Traditional mechanical Deairing
Study NCT03961425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Cannula
Description: NON specific, low cost delivery system
Study NCT03961425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Cardia
Description: Specific Commercial CO2 Diffuser
Study NCT01056666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conveen Optima is a urisheath to be used together with a collecting bag for urine
Description: Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
Study NCT01056666 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: absorbent protection
Description: The patient use his usual absorbent protection (same brand), and change it when needed
Study NCT01173211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
Study NCT01173211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
Study NCT01173211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
Study NCT04813081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
Study NCT02642367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Description: without use of stylet
Study NCT02642367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)
Description: use of stylet
Study NCT02642367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
Study NCT02642367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
Study NCT00940693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: 60 mg capsule once per day for 6 weeks
Study NCT00940693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one capsule of placebo taken one a day for 6 weeks
Study NCT03839121 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Observation and documentation of CRT patients
Study NCT01372033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 18 sessions of CBT, twice weekly
Study NCT02442128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol /Fentanyl
Description: fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Study NCT02442128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl / propofol
Description: fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Study NCT02695459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum and everolimus
Description: Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
Study NCT01372033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 18 sessions with goals groups drug testing
Study NCT01517880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER)
Description: SA-ER will be administered in doses of 3000mg per day or 6000mg per day
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 MG/ML
Description: Dosing to be performed by subcutaneous injection in clinic
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10Mg Tablet
Description: Patients will be instructed to take once daily at night.
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03545828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-channel aEEG monitoring
Description: 18 channel aEEG monitoring in comatose TTM-treated patients
Study NCT03100422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARMin
Description: arm therapy robot
Study NCT03100422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: bilateral arm training
Study NCT03494894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Middle meatus aspirations and sputum
Description: Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\]
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate